, Volume 19, Issue 3, pp 131–137 | Cite as

Drug-resistant tuberculosis: an insurmountable epidemic?



Drug-resistant tuberculosis has brought back the spectre of pre-antibiotic days. WHO surveillance data from 2007 showed multi-drug-resistant tuberculosis (MDR-TB)—tubercle bacillus resistant to both isoniazid and rifampicin accounting for 4.8% of all new and subsequent cases of tuberculosis. India and China—the two most populated countries of the world, house the maximum number of drug-resistant tuberculosis cases. In eastern European and central Asian countries, more than 6% of new TB cases are MDR-TB, whereas the number is <3% in the countries of the western world. Extensively drug-resistant tuberculosis (XDR-TB) has emerged with the prospect of tuberculosis becoming an incurable disease. A surveillance spreading over the six continents showed 10% of MDR-TB cases were also XDR-TB. The fact that tuberculosis is the most common opportunistic infection among HIV-infected patients in developing countries makes the challenge almost insurmountable. The mortality of HIV and MDR-TB co-infected patients is exceedingly high. The absence of guidelines for treatment of drug-resistant tuberculosis and of infrastructure for delivery of DOT program and rapid laboratory diagnostic facilities, including drug susceptibility testing for both first and second-line drugs, and lack of trained human resource in most of the developing world account for the emergence and perpetuation of this menacing problem. WHO along with partnership with Green Light Committee and individual national governments has started DOT plus program to control this global epidemic.


Tuberculosis Multi-drug-resistant tuberculosis (MDR-TB) Extensively drug-resistant tuberculosis (XDR-TB) Directly observed treatment (DOT) 


  1. Abdool Karim SS, Naidoo K, Grober A, Padayatchi N et al (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. NEJM 362:697–706PubMedCrossRefGoogle Scholar
  2. Acuna-Villaordune C, Vassal A, Henostroza G et al (2008) Cost-effectiveness analysis of introduction of rapid alternative methods to identify multi drug resistant tuberculosis in middle-income countries. Clin Infect Dis 47:487–495CrossRefGoogle Scholar
  3. Boehme CC, Nabeta P, Hillermann D et al (2010) Rapid molecular detection of Tuberculosis and Rifampin resistance. NEJM 363:1005–1015PubMedCrossRefGoogle Scholar
  4. Diacon AH, Alexander P, Martin G et al (2010) The diarylquinoline TMC 207 for multidrug resistant tuberculosis. N Engl J Med 360(23):2397–2405Google Scholar
  5. Espinal MA, Laszlo A, Simonsen L et al (2001) Global trends in the resistance to antituberculosis drugs. NEJM 344:1294–1303PubMedCrossRefGoogle Scholar
  6. Gandhi NR, Moll A, Sturm AW et al (2006) Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 365:1575–1580CrossRefGoogle Scholar
  7. Gupta R, Cegielski JP, Espinal MA, Henkens M et al (2002) Increasing transparency in partnership for health introducing the Green Light Committee. Trop Med Int Health 7:970–976PubMedCrossRefGoogle Scholar
  8. Keshavjee S, Gelmanova IY, Farmer PE et al (2008) Treatment of extensively drug resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372:1403–1409PubMedCrossRefGoogle Scholar
  9. Keshavjee S, Farmer PE et al (2010) Picking up the pace: scale-up of MDR Tuberculosis Treatment Programs. NEJM 363:1781–1784PubMedCrossRefGoogle Scholar
  10. Kim H-R, Hwang SS, Kim HJ et al (2007) Impact of extensive drug resistance on treatment outcomes in non-HIV infected patients with multidrug resistant tuberculosis. Clin Infect Dis 45:1290–1295PubMedCrossRefGoogle Scholar
  11. Mak A, Thomas A, del Granado M, Zaleskis R et al (2008) Influence of multidrug resistance on tuberculosis treatment outcome with standardized regimens. Am J Respir Crit Care Med 178:306–312PubMedCrossRefGoogle Scholar
  12. Migliori GB, Ortmann J, Girardi E et al (2007) Extensively drug resistant tuberculosis, in Italy and Germany. Emerg Infect Dis 13:780–781PubMedGoogle Scholar
  13. Mitnick CD, Shin SS, Seung KJ et al (2008) Comprehensive treatment of extensively drug resistant tuberculosis. NEJM 359:563–574PubMedCrossRefGoogle Scholar
  14. Mohan AK, Cote TR, Block JA et al (2004) Tuberculosis following the use of etanercept, a tumour necrosis factor inhibitor. Clin Infect Dis 39:296–299CrossRefGoogle Scholar
  15. MMWR (2006) Morb Mortal Wkly Rep 55:301Google Scholar
  16. Mukherjee JS, Michael LR, Adrienne RS et al (2004) Lancet 363:474–481Google Scholar
  17. Piatck AS, Talenti A, Murray MR et al (2000) Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44:103–110CrossRefGoogle Scholar
  18. Sacks LV, Pendle S, Orlovic D, Blumberg L, Constantinou C (1999) A comparison of outbreak- and nonoutbreak-related MDR-TB among HIV infected patients in a South African hospital. Clin Infect Dis 29(1):96–101PubMedCrossRefGoogle Scholar
  19. Scano F, Vitoria M, Burman W, Harries AD et al (2008) Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 12(12):1370–1375PubMedGoogle Scholar
  20. Shah NS, Robert B, Armstrong L et al (2008) Extensively drug resistant tuberculosis in USA, 1993–2007, JAMA 300(18):2153–2160Google Scholar
  21. Telent A, Imbodem P, Marcheri F et al (1993) Detection of rifampicin resistance in Mycobacterium tuberculosis. Lancet 341:647–650CrossRefGoogle Scholar
  22. WHO (2006) Guideline for programmatic management of drug resistant tuberculosis. WHO, GenevaGoogle Scholar
  23. WHO (2008) Guideline for programmatic management of drug resistant tuberculosis. WHO, GenevaGoogle Scholar
  24. WHO Report (2006) Stop TB strategyGoogle Scholar
  25. WHO Report (2009) Global Tuberculosis ControlGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  1. 1.Department of Medicine, Faculty of Health ScienceHamilton Health Sciences & McMaster UniversityHamiltonCanada

Personalised recommendations